Optimizing Platelet Isolation (The Cell Study)

Active, not recruiting

• Conditions: Healthy

• Registration Number: NCT04470505
• Lead Sponsor: Arkansas Children's Hospital Research Institute

Brief Summary

The research study is about blood cells (platelets) and their power houses (mitochondria). The investigators want to learn about their behavior in order to ensure that our laboratory procedures are generating optimal results.

Detailed Description

The objectives of this study are to assess platelet activation following standard laboratory procedures used in the process of measuring platelet mitochondrial function, and to determine the optimal amount of digitonin needed to permeabilize platelet cell membrane.

Study Timeline

• Study First Submitted: 2020-07-02
• Study Start: 2020-07-06
• Study First Submitted QC: 2020-07-13
• Study First Posted: 2020-07-14
• Primary Completion: 2023-09-01
• Status Verified: 2023-12
• Last Update Submitted: 2024-01-31
• Last Update Posted: 2024-02-01
• Study Completion: 2024-12-20

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Age 25-35
• All races
• All ethnicity
• 18.5 - 30 BMI

Exclusion Criteria

• smoking
• Aspirin intake
• Recreational drug use
• Alcohol intake more than 3 times per week
• Self-reported possibility of current pregnancy
• Known diagnosis of:
• Pre-diabetes
• Diabetes
• High cholesterol
• High triglycerides
• Hypertension
• Anemia
• Autism spectrum disorder
• Attention deficit hyperactivity disorder (ADHD)
• Attention deficit disorder (ADD)
• Severe asthma
• Refusal to stop taking nutritional supplements
• Any other pre-existing medical condition that requires daily medication as determined by the investigators to affect outcome of interest

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Platelet activation from isolated platelets	day 1	Whole blood will be collected following an overnight fast, and platelets isolated using standard procedures. Platelet activation markers (e.g., CD62P ) will be measured using flow cytometric analysis.

Secondary Outcome Measures

Name	Time	Method
Platelet activation measured in whole blood	day 1	Whole blood will be collected following an overnight fast. Platelet activation will be measured in whole blood by the expression CD62P
Platelet reactivity measured in whole blood	day 1	Whole blood will be collected following an overnight fast. Platelet reactivity will be measured in whole blood with adenosine diphosphate (ADP).

Trial Locations

Locations (1)

Arkansas Children's Nutrition Center; 🇺🇸 Little Rock, Arkansas, United States